

10/55623  
Rec'd PTO 04 NOV 2005

PCT / IB 04 / 01424  
21 MAY 2004



BEST AVAILABLE COPY

REC'D 21 MAY 2004

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
ORGANISATION MONDIALE DE LA PROPRIÉTÉ INTELLECTUELLE

34, chemin des Colombettes, Case postale 18, CH-1211 Genève 20 (Suisse)  
Téléphone: (41 22) 338 91 11 - e-mail: wipo.mail@wipo.int. - Fac-similé: (41 22) 733 54 28

PATENT COOPERATION TREATY (PCT)  
TRAITÉ DE COOPÉRATION EN MATIÈRE DE BREVETS (PCT)

CERTIFIED COPY OF THE INTERNATIONAL APPLICATION AS FILED  
AND OF ANY CORRECTIONS THERETO

COPIE CERTIFIÉE CONFORME DE LA DEMANDE INTERNATIONALE, TELLE QU'ELLE  
A ÉTÉ DÉPOSÉE, AINSI QUE DE TOUTES CORRECTIONS Y RELATIVES

International Application No. } PCT/IB 03 / 01771  
Demande internationale n° }

International Filing Date  
Date du dépôt international }

06 MAY 2003  
(06.05.03)

Geneva/Genève, 21 MAY 2004  
(21.05.04)

International Bureau of the  
World Intellectual Property Organization (WIPO)

Bureau International de l'Organisation Mondiale  
de la Propriété Intellectuelle (OMPI)

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(b) OR (b)



J.-L. Baron

Head, PCT Receiving Office Section  
Chef de la section "office récepteur du PCT"

IAB

1/5

RLL-250WO

PCT REQUEST

Original (for SUBMISSION) - printed on 06.05.2003 04:09:44 PM

0	For receiving Office use only	PCT/IB 03/01771
0-1	International Application No.	
0-2	International Filing Date	06 MAY 2003 (06.05.03)
0-3	Name of receiving Office and "PCT International Application"	INTERNATIONAL BUREAU OF WIPO PCT International Application
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	PCT-EASY Version 2.92 (updated 01.04.2003)
0-5	Petition	The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty
0-6	Receiving Office (specified by the applicant)	International Bureau of the World Intellectual Property Organization (RO/IB)
0-7	Applicant's or agent's file reference	RLL-250WO
I	Title of invention	MONOCOMPARTMENT OSMOTIC CONTROLLED DRUG DELIVERY SYSTEM
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	RANBAXY LABORATORIES LIMITED
II-5	Address:	19, Nehru Place 110019 New Delhi, Delhi India
II-6	State of nationality	IN
II-7	State of residence	IN
II-8	Telephone No.	91 11 2645 2666
II-9	Facsimile No.	91 11 2600 2074
II-10	e-mail	jay.deshmukh@ranbaxy.com
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	VISWANATHAN, Narayanan, Badri
III-1-5	Address:	Plot No. 35, 2nd Main Road Kannan Nagar, Madipakkam 600 091 Chennai, Tamil Nadu India
III-1-6	State of nationality	IN
III-1-7	State of residence	IN

## PCT REQUEST

Original (for SUBMISSION) - printed on 06.05.2003 04:09:44 PM

III-2	Applicant and/or Inventor	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	SANKAR, Ramakrishnan
III-2-5	Address:	24, River Bank Street Madukkur 614903 Thanjavur District, Tamil Nadu India
III-2-6	State of nationality	IN
III-2-7	State of residence	IN
III-3	Applicant and/or Inventor	
III-3-1	This person is:	applicant and inventor
III-3-2	Applicant for	US only
III-3-4	Name (LAST, First)	VERMA, Rajan, Kumar
III-3-5	Address:	House Number 1366-A Gali Sunaran, Najafgarh 110043 New Delhi, Delhi India
III-3-6	State of nationality	IN
III-3-7	State of residence	IN
III-4	Applicant and/or Inventor	
III-4-1	This person is:	applicant and inventor
III-4-2	Applicant for	US only
III-4-4	Name (LAST, First)	RAGHUVANSHI, Rajeev, Singh
III-4-5	Address:	D8/8131 Vasant Kunj 110070 New Delhi, Delhi India
III-4-6	State of nationality	IN
III-4-7	State of residence	IN
III-5	Applicant and/or Inventor	
III-5-1	This person is:	applicant and inventor
III-5-2	Applicant for	US only
III-5-4	Name (LAST, First)	RAMPAL, Ashok, Kumar
III-5-5	Address:	14, Sewa Nagar Ram Tirath Road 143001 Amritsar, Punjab India
III-5-6	State of nationality	IN
III-5-7	State of residence	IN

## PCT REQUEST

Original (for SUBMISSION) - printed on 06.05.2003 04:09:44 PM

IV-1	Agent or common representative; or address for correspondence No agent or common representative is/has been appointed; the following special address should be used as: Name	address for correspondence  RANBAXY LABORATORIES LIMITED c/o DESHMUKH, Jayadeep R. 600 College Road East, Suite 2100 Princeton, NJ 08540 United States of America
IV-1-1		
IV-1-2	Address:	
IV-1-3	Telephone No.	609 720 5608
IV-1-4	Facsimile No.	609 514 9779
IV-1-5	e-mail	jay.deshmukh@ranbaxy.com
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

## PCT REQUEST

Original (for SUBMISSION) - printed on 06.05.2003 04:09:44 PM

V-5	Precautionary Designation Statement  In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.		
V-6	Exclusion(s) from precautionary designations	NONE	
VI-1	Priority claim of earlier national application		
VI-1-1	Filing date	06 May 2002 (06.05.2002)	
VI-1-2	Number	530/Del/2002	
VI-1-3	Country	IN	
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)	
VIII	Declarations	Number of declarations	
VIII-1	Declaration as to the identity of the inventor	-	
VIII-2	Declaration as to the applicant's entitlement, as at the International filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's entitlement, as at the International filing date, to claim the priority of the earlier application	-	
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	
IX	Check list	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	5	-
IX-2	Description	22	-
IX-3	Claims	5	-
IX-4	Abstract	1	EZABST00.TXT
IX-5	Drawings	5	-
IX-7	TOTAL	38	
	Accompanying items	paper document(s) attached	electronic file(s) attached
IX-8	Fee calculation sheet	✓	-
IX-17	PCT-EASY diskette	-	Diskette
IX-18	Other (specified):	Transmittal Letter	-
IX-19	Figure of the drawings which should accompany the abstract	1	
IX-20	Language of filing of the International application	English	

## PCT REQUEST

Original (for SUBMISSION) - printed on 06.05.2003 04:09:44 PM

X-1	Signature of applicant, agent or common representative	
X-1-1	Name	RANBAXY LABORATORIES LIMITED
X-1-2	Name of signatory	Jay R. Deshmukh
X-1-3	Capacity	Vice President - Intellectual Property
X-2	Signature of applicant, agent or common representative	
X-2-1	Name (LAST, First)	VISWANATHAN, Narayanan, Badri
X-3	Signature of applicant, agent or common representative	
X-3-1	Name (LAST, First)	SANKAR, Ramakrishnan
X-4	Signature of applicant, agent or common representative	
X-4-1	Name (LAST, First)	VERMA, Rajan, Kumar
X-5	Signature of applicant, agent or common representative	
X-5-1	Name (LAST, First)	RAGHUVANSHTI, Rajeev, Singh
X-6	Signature of applicant, agent or common representative	
X-6-1	Name (LAST, First)	RAMPAL, Ashok, Kumar

## FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	06 MAY 2003	(03.05.03)
10-2	Drawings:		
10-2-1	Received		
10-2-2	Not received		
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported International application		
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)		
10-5	International Searching Authority	ISA/EP	
10-6	Transmittal of search copy delayed until search fee is paid		

## FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau
------	--





13.05.03

RLL-250WO

## PCT REQUEST

Original (for SUBMISSION) - printed on 06.05.2003 04:09:44 PM

5/5

X-1	Signature of applicant, agent or common representative	
X-1-1	Name	RANBAXY LABORATORIES LIMITED
X-1-2	Name of signatory	Jay R. Deshmukh
X-1-3	Capacity	Vice President - Intellectual Property
X-2	Signature of applicant, agent or common representative	
X-2-1	Name (LAST, First)	VISWANATHAN, Narayanan, Nadri
X-3	Signature of applicant, agent or common representative	
X-3-1	Name (LAST, First)	SANKAR, Ramakrishnan
X-4	Signature of applicant, agent or common representative	
X-4-1	Name (LAST, First)	VERMA, Rajan, Kumar
X-5	Signature of applicant, agent or common representative	
X-5-1	Name (LAST, First)	RAGHUVANSHI, Rajeev, Singh
X-6	Signature of applicant, agent or common representative	
X-6-1	Name (LAST, First)	RAMPAL, Ashok, Kumar

## FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported International application	06 MAY 2003 (06.05.03)
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported International application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

## FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

RLL-250WO

PCT/IB03/01771

## MONOCOMPARTMENT OSMOTIC CONTROLLED DRUG DELIVERY SYSTEM

### Field of the Invention

5 The present invention relates to a monocompartment osmotic controlled drug delivery system comprising a poorly soluble drug and at least one alginic acid derivative.

### Background of the Invention

Advantages of controlled release drug delivery systems are well documented.

10 Numerous technologies have been exploited to achieve desired drug release profiles, as required to satisfy therapeutic needs and patient compliance. One such widely used controlled release technology is based on osmotic pressure controlled drug delivery, introduced by F. Theewas in J. Pharm. Sci., Vol. 64, 12, 1987-91 (1975). The elementary oral osmotic system (OROS<sup>®</sup>, Alza Corp.) in its simplest version takes the form of a  
15 conventional coated tablet. It comprises a homogenous core tablet of drug coated with a semi-permeable wall/layer and an aperture created through the wall for the release of contents from the core. When placed in dissolution media/gastrointestinal fluid, water permeates into the core through the semipermeable wall and dissolves the drug. The osmotic pressure thus built exerts pressure against the wall and thereby releases out the  
20 solution of drug through the aperture in the wall.

Osmotic controlled drug delivery systems show better *in vitro-in vivo* correlation as their performance is reported to be independent of pH and contents of the gastrointestinal tract. Moreover, they are highly resistant to mechanical stress encountered  
25 within the gut. Hence, properly designed osmotic systems may prove to be of paramount importance.

Use of simple osmotic system designed by F. Theewas is confined to a limited number of drugs, which are soluble enough to produce a sufficiently high osmotic pressure. Sparingly soluble drugs fail to be delivered from this system in the desired manner, and therefore demand skillful modifications of the Theewas design to exploit the advantages of these osmotic delivery systems.

U.S. Patent No. 4,111,202 assigned to Alza Corp. addresses this problem by the fabrication of a "push-pull" (double compartment core) osmotic system wherein the core of the OROS® system, described above, is replaced by a pull compartment containing a sparingly soluble drug composition and a push compartment containing water soluble 5 osmotically active agents. The two compartments are separated by means of an elastic diaphragm. When in operation, the osmotic pressure that builds up in the push compartment causes an increase in its volume. This increase in volume expands the elastic diaphragm, which thereby forces the drug out of the pull compartment through an aperture. Though advantageous over the OROS® system, manufacturing of "push-pull" 10 systems is technically complicated and costly, requiring proper placement of elastic diaphragm between the two compartments. Further, for sparingly soluble drugs having large therapeutic doses, unacceptably large sized "push-pull" systems are needed.

The concept of "push-pull" systems is further simplified, as described in European 15 Patent Application No. 52917, by developing osmotic systems without the elastic diaphragm. The osmotic system disclosed in this patent application has the two compartments of the push pull system replaced by two different composition layers, viz., drug layer containing drug and osmotic agents, and an expandable driving member layer 20 formed of a water swellable hydrogel that absorbs fluid imbibed into the compartment and expands from a rested to an expanded state. The expansion of the driving member exerts pressure on the drug layer forcing its content out of the aperture. Manufacturing of the above system is still problematic, requiring multiple compression steps and a high level of uniformity in the grain size of granulate during compression. Identification of drug layer 25 surface for drilling of aperture through the semipermeable wall is also cumbersome.

25

The above problems are overcome by a homogeneous monocompartment osmotic system disclosed in U.S. Patent No. 4,857,336 reissued as Re 34,990 and U.S. Patent No. 4,992,278, both assigned to Ciba-Geigy. U.S. Patent No. 4,992,278 discloses a monocompartment therapeutic system comprising (a) a casing made of a material that is 30 permeable to water and is impermeable to the components of the core containing the active ingredient; (b) a core containing an active ingredient that is sparingly soluble in water or a mixture of such active ingredients, a hydrophilic polymeric swelling agent consisting of a mixture of a vinylpyrrolidone / vinyl acetate copolymer with an ethylene oxide homopolymer, optionally water soluble substance for inducing osmosis and

optionally further pharmaceutically acceptable adjuncts; and (c) passage through the casing (a) for the transport of the constituents contained in the core into the surrounding aqueous body fluid. Further, this patent teaches that the use of conventional swelling agents of two-compartment system such as polyvinylpyrrolidone, polyethylene oxide, 5 polymethacrylate and the like, in single compartment system does not work. This is because the swelling pressure of these polymers is so great that in contact with water the semipermeable membrane bursts and the whole system disintegrates in the stomach after a short period of time.

10 There is thus a need for logical selection of a suitable swelling agent that enables easy fabrication of monocompartment system as well as provide controlled swelling without rupturing the semipermeable membrane. On the other hand, the swelling pressure should be sufficient enough to force the contents out of the system and achieve desired controlled drug release profiles.

15

#### Summary of the Invention

We have discovered that use of at least one alginic acid derivative as swelling agent in a monocompartment osmotic controlled drug delivery system overcomes the above problems and helps in achieving desired controlled drug release profiles for a poorly 20 soluble drug.

In one general aspect, there is provided a monocompartment osmotic controlled drug delivery system that includes a poorly soluble drug and at least one alginic acid derivative.

25

Embodiments of the monocompartment osmotic controlled drug delivery system may include one or more of the following features. For example, the monocompartment osmotic controlled drug delivery system may further include a core, a semipermeable membrane enclosing at least a part of the core, and at least one passageway in the 30 semipermeable membrane configured to deliver the contents of the core into the surrounding media. The core comprises the poorly soluble drug, the at least one alginic acid derivative, and at least one pharmaceutically acceptable inert excipient.

RLL-250WO

The core may further include an osmotic agent. The core may further include one or more additional layers below and/or above the semipermeable membrane. The one or more additional layers may include an immediate release layer of drug and the drug may be the same or different drug as in the core. The core may have a compact composition  
5 having a shape.

The poorly soluble drug may be a single drug or a combination of drugs. The poorly soluble drug may be one or more of an antidiabetic, antineoplastic agent, antihypertensive, psychopharmacological agent, cardiovascular agent, platelet aggregation 10 inhibitor, analgesic, antimicrobial, diuretic, or spasmolytic. The poorly soluble drug may be one or more of glipizide, doxazosin, verapamil, prazosin, isradipine, cilostazol, nisoldipine, bendroflumethiazide, chlorpropamide, hydrocortisone, ibuprofen, and diclofenac. The poorly soluble drug may be either of glipizide, doxazosin, or 15 cilostazol. The poorly soluble drug may be glipizide present at either of approximately 2.5 mg, 5 mg or 10 mg.

The alginic acid derivative may be one or more of alginic acid and its pharmaceutically acceptable salts, pharmaceutically acceptable esters, or other pharmaceutically acceptable derivatives. The alginic acid salt may be one or more salts of 20 alginic acid with sodium, potassium, magnesium, calcium or ammonia. The salt of alginic acid may be sodium alginate. The alginic acid ester may be propylene glycol alginate.

The pharmaceutically acceptable inert excipient may be one or more of binders, diluents, surfactants, pH modifiers, lubricants/glidants, stabilizers, plasticizers, and 25 coloring agents.

The semipermeable membrane may be one or more of semipermeable membrane-forming polymers and coating additives. The semipermeable membrane-forming polymer may be one or more of cellulose derivatives, cellulose acetate, cellulose triacetate, agar 30 acetate, amylose acetate, cellulose acetate ethyl carbamate, cellulose acetate phthalate, cellulose acetate methyl carbamate, cellulose acetate succinate, cellulose acetate dimethylaminoacetate, cellulose acetate ethyl carbonate, cellulose acetate chloroacetate, cellulose acetate ethyl oxalate, cellulose acetate methyl sulphonate, cellulose acetate butyl sulphonate, cellulose acetate propionate, cellulose acetate diethylamino-acetate, cellulose

RLL-250WO

PCT/IB03/01771

acetate octate, cellulose acetate laurate, cellulose acetate p-toluenesulphonate, cellulose acetate butyrate, polymeric epoxides, copolymers of alkylene oxides and alkyl glycidyl ethers, polyglycols, polylactic acid derivatives, and copolymers of acrylic acid ethyl ester and methacrylic acid methyl ester. The cellulose derivative may be cellulose acetate. The 5 semipermeable membrane-forming polymer may be a combination of cellulose acetates having different degrees of acetylation.

The coating additives may be one or more of flux enhancers and pharmaceutically acceptable inert excipients. The flux enhancer may be one or more of hydroxymethyl 10 cellulose, hydroxypropyl methylcellulose, polyethylene glycol, hydroxypropylcellulose, propylene glycol, and polyvinylpyrrolidone. The flux enhancer may be hydroxypropyl methylcellulose. The flux enhancer may be polyethylene glycol.

The osmotic agent may be one or more of water soluble salts of inorganic acids, 15 water soluble salts of organic acids, non ionic organic compounds having high water solubility, water-soluble amino acids, urea, and urca derivatives. The one or more water soluble salts of inorganic acids may include magnesium chloride, magnesium sulfate, lithium chloride, sodium chloride, potassium chloride, lithium hydrogen phosphate, sodium hydrogen phosphate, potassium hydrogen phosphate, lithium dihydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen phosphate. The 20 water soluble salts of organic acids may be one or more of sodium acetate, potassium acetate, magnesium succinate, sodium benzoate, sodium citrate, and sodium ascorbate. The non ionic organic compounds having high water solubility may be one or more carbohydrates, wherein carbohydrates includes one or more of mannitol, sorbitol, 25 arabinose, ribose, xylose, glucose, fructose, mannose, galactose, sucrose, maltose, lactose, and raffinose. The water-soluble amino acids may be one or more of glycine, leucine, alanine, and methionine. The osmotic agent may be sorbitol or lactose.

In another general aspect, there is provided a process for preparing a 30 monocompartment osmotic controlled drug delivery device includes blending a poorly soluble drug, at least one alginic acid derivative, and at least one pharmaceutically acceptable inert excipient; and compressing the blend into a compact core;

RLL-250WO

PCT/IB03/01771

enclosing the core with a solution/dispersion of an enclosing composition comprising one or more semipermeable membrane-forming polymers and other coating additives; and forming at least one passageway in the semipermeable membrane.

5

Embodiments of the process may include one or more of the following features. For example, the process may further include granulating the blend with a binder before compressing the blend into a compact core. The process may further include blending at least one alginic acid derivative with the blend. The solution/dispersion of the enclosing composition may be made in a solvent that includes one or more of dichloromethane, isopropyl alcohol, acetone, methanol, ethanol, and water. The granulation may be made in a solvent that includes one or more of dichloromethane, isopropyl alcohol, acetone, methanol, ethanol, and water.

15

In another general aspect, a method of achieving controlled delivery of a poorly soluble drug over a period of at least 4 hours includes providing a monocompartment osmotic controlled drug delivery system comprising a poorly soluble drug and at least one alginic acid derivative.

20

The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and the claims.

#### Brief Description of the Drawings

25

Fig-1 is a graph that compares the *in vitro* release of drug (glipizide) from monocompartment osmotic controlled drug delivery systems as per the composition of Examples 1a, 1b and 1c.

30

Fig-2 is a graph that compares the *in vitro* release of drug (glipizide) from monocompartment osmotic controlled drug delivery systems as per the composition of Examples 2a, 2b and 2c.

Fig-3 is a graph that compares the *in vitro* release of drug (glipizide) from five different sets of monocompartment osmotic controlled drug delivery systems as per the

RLL-250WO

compositions of Example 3, with semipermeable membrane thickness equivalent to weight gains of 11, 13, 15, 18 and 20% of core weight respectively.

Fig-4 is a graph that compares the *in vitro* release of drug (doxazosin mesylate) from monocompartment osmotic controlled drug delivery systems as per composition of Examples 4a, 4b, 4c and 4d.

Fig-5 is a graph that compares the *in vitro* release of drug (cilostazol) from monocompartment osmotic controlled drug delivery systems as per composition of Examples 5, with semipermeable membrane thickness equivalent to weight gains of 7.6 and 10.8% of core weight respectively.

#### Description of the Invention

Alginic acid derivatives used as a swelling agent in the monocompartment osmotic controlled drug delivery system possess the required swelling property to form a dispersion of the poorly soluble drug of a consistency that is easily flowable through the passageway without damaging the semipermeable membrane. A combination of above attributes is rarely found amongst conventionally used swelling agents in osmotic systems. Moreover, the amount of alginic acid derivative used in the core may be varied over a wide range. Most of the alginic acid derivatives have been proven to be non-toxic to humans and other mammals on oral administration and are approved for human consumption. Further, with proper choice and use of a varying amount of osmotic agents and other pharmaceutically acceptable inert excipients, the drug delivery system may be designed to achieve drug release profiles of varied nature. The rate of drug release may also be manipulated by controlling the thickness and nature of semipermeable membrane, e.g., with a proper choice of other coating additives.

When the monocompartment osmotic controlled drug delivery system of the present invention is placed in dissolution media/gastrointestinal fluid, water permeates into the core, through the semipermeable membrane. Absorption of water causes swelling of the alginic acid derivative in the core, which thereby exerts pressure against the semipermeable membrane and forces the dispersion of poorly soluble drug through the passageway into the surrounding media. On coming out of the system, the drug in the dispersion is dissolved in the surrounding media.

The term "swelling" as used herein refers to an increase in the volume on coming in contact to water. In some cases swelling may even lead to a formation of a gel like consistency into which the poorly soluble drug is embedded in the form of dispersion. Hence, the terms "swelling" and "gelling" are used interchangeably herein.

5

The term "core" as used herein refers to and includes any compact composition having a defined shape such as tablet, mold, capsule and the like.

The term "poorly soluble drug" as used herein includes drugs having solubility of 10 about 1 part in 25 or more parts of water. It also includes those drugs wherein 1 part of the drug dissolves in less than 25 parts of water, but under acidic or alkaline conditions, or under the influence of other excipients the solubility is decreased up to 1 in 25 parts of water. Suitable examples of the therapeutic classes, for the purpose of the present invention include antidiabetics, antineoplastic agents, antihypertensives, 15 psychopharmacological agents, cardiovascular agents, platelet aggregation inhibitors, analgesics, antimicrobials, diuretics, spasmolytics and the like. Specific examples of poorly soluble drugs include glipizide, doxazosin, verapamil, prazosin, isradipine, cilostazol, nifedipine, nisoldipine, bendroflumethazide, chlorpropamide, hydrocortisone, ibuprofen, diclofenac, and the like, and combinations thereof. The term "drug" as used 20 herein includes free drug as well as any pharmaceutically acceptable salt thereof. The poorly soluble drug as used herein may be in a commercially available form as such; or in a processed form using techniques of comminution, micro emulsification, co-melting, solid dispersion, spray drying, co-processing with pharmaceutically acceptable inert excipients, drug-inclusion complexation and the like.

25

"Alginic acid derivative" as used herein include alginic acid as well as any of its pharmaceutically acceptable derivative such as salts, esters, and the like, and mixtures thereof. Specific examples of alginic acid salts include salts of alginic acid with sodium, potassium, magnesium, calcium or ammonia. Specific alginic acid esters include 30 propylene glycol alginate.

Alginic acid is a naturally occurring hydrophilic colloidal polysaccharide consisting mainly of residues of  $\beta$ -1,4-linked D-mannuronic acid and  $\alpha$ -1,4-linked L-

RLL-250WO

PCT/IB03/01771

glucuronic acid. Depending on the species of kelp used in manufacturing, ratios of mannuronic acid to glucuronic acid content typically range from 0.4 to 0.9. Alginic acid has an average molecular weight varying from about 10,000-6,00,000 and is widely used in the pharmaceutical field as a stabilizer, thickener, gelling agent and emulsifier. It is 5 insoluble in water but its salts form thermally irreversible gels with water, whose viscosity decreases at higher pH values. Alginic acid derivatives are marketed by a white to yellowish brown filamentous, grainy, granular or powdered form under one or more of the nonexclusive list of the trade names - KELACID®, ALGINIC ACID HF/D, ALGINIC ACID DC, KELTONE® LVCR, KELTONE® HVCR, MANUCOL® LKX, MANUCOL 10 LB, MANUCOL DMF, KELCOSOL®, MANUGEL® DMB, KELCOLOID® LVF, MANUCOL ESTER ERK, Improved KELMAR®, KELTOSE®. Based on the grade used and desired drug release profile, the amount of alginic acid derivative may vary from about 5% to about 98% by weight of the total weight of core.

15 One of the important factors in achieving effective hydration, and thereby controlled swelling of the alginic acid derivative, is proper dispersion of individual particles into the core. Poor dispersion may lead to the formation of large lumps of unhydrated alginic acid derivative and significantly extend the hydration and swelling time which can produce erratic drug release profiles.

20 One way of achieving proper dispersion of alginic acid derivative particles is blending with an osmotic agent, which diminishes its tendency to form lumps. Further, the osmotic agent may be used to manipulate the viscosity of the dispersion of poorly soluble drug formed in the core, and also to manipulate drug release profile.

25 The term "osmotic agent" as used herein includes all pharmaceutically acceptable inert water soluble compounds suitable for inducing osmosis as referred to in, for example, the Pharmcoepias, "Hager," and Remington's Pharmaceutical Sciences. Examples of compounds suitable as osmotic agents include water soluble salts of inorganic acids such 30 as magnesium chloride or magnesium sulfate, lithium chloride, sodium chloride, potassium chloride, lithium hydrogen phosphate, sodium hydrogen phosphate, potassium hydrogen phosphate, lithium dihydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen phosphate; water soluble salts of organic acids such as sodium acetate, potassium acetate, magnesium succinate, sodium benzoate, sodium citrate, and

RI.I.-250WO

sodium ascorbate; non ionic organic compounds with high water solubility, e.g., carbohydrates such as mannitol, sorbitol, arabinose, ribose, xylose, glucose, fructose, mannose, galactose, sucrose, maltose, lactose, and raffinose; water-soluble amino acids such as glycine, leucine, alanine, and methionine; urea and urca derivatives; and the like and mixtures thereof. The amount of osmotic agent used in the core may be up to about 60% by weight of the total weight of core.

“Semipermeable membrane” as used herein is a membrane or coating that allows movement of water molecules through it but does not allow the contents of the core to pass through. The semipermeable membrane of the drug delivery system includes one or more membrane-forming polymers and other pharmaceutically acceptable coating additives. Membrane-forming polymers are those that are not metabolized in the gastrointestinal tract, i.e., are ejected unchanged from the body in feces. Membrane-forming polymers also include those known in the art for fabrication of semipermeable membrane and described in the literature, e.g., in U.S. Patent Nos. 3,916,899 and 3,977,404. Examples of semipermeable membrane forming polymers include cellulose derivatives such as cellulose acetate, cellulose triacetate, agar acetate, amylose acetate, cellulose acetate ethyl carbamate, cellulose acetate phthalate, cellulose acetate methyl carbamate, cellulose acetate succinate, cellulose acetate dimethylaminoacetate, cellulose acetate ethyl carbonate, cellulose acetate chloroacetate, cellulose acetate ethyl oxalate, cellulose acetate methyl sulphonate, cellulose acetate butyl sulphonate, cellulose acetate propionate, cellulose acetate diethylamino-acetate, cellulose acetate octate, cellulose acetate laurate, cellulose acetate p-toluenesulphonate, and cellulose acetate butyrate; polymeric epoxides; copolymers of alkylene oxides and alkyl glycidyl ethers; polyglycols or polylactic acid derivatives; copolymer of acrylic acid ethyl ester and methacrylic acid methyl ester; and the like; and mixtures thereof. Alternatively, a combination of cellulose acetates with different degrees of acetylation may be used as membrane-forming polymer. As the degree of acetylation of cellulose acetate increases, permeability of the membrane decreases. In particular, a combination of cellulose acetates having acetyl content in the range of about 8% to about 50% may be used. Further, other coating additives may be combined with the membrane forming polymers to adjust the permeability as desired. Controlling membrane thickness also helps to manipulate the permeability of the membrane, which may vary from about 3% to about 40% weight build up over the weight of core.

The term "passageway" as used herein refers to and includes any suitable means for releasing the contents of the core into the surrounding media. The term includes passages, apertures, bores, holes, openings and the like, created through the semipermeable membrane and forming a connection between the core and the surrounding media. The passageway may be created by mechanical drilling or laser drilling, or formed in response to the osmotic pressure acting on the drug delivery system. Based on the nature of desired drug release profile, the number and diameter of the passageway may be adjusted. However, the diameter of the passageway should not be large enough to allow body fluids to enter the drug delivery system by the process of convection.

10

The term "pharmaceutically acceptable inert excipients" as used herein includes all excipients used in the art of manufacturing osmotic controlled dosage forms and described in the literature. Examples include binders, diluents, surfactants, pH modifiers, lubricants/glidants, stabilizers, plasticizers, coloring agents, and the like, and mixtures thereof.

Specific examples of binders include methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate,

20 propylene glycol, and the like, and mixtures thereof.

Specific examples of diluents include calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrates, dextrose excipients, fructose, kaolin, lactitol, lactose, 25 mannitol, sorbitol, starch, pregelatinized starch, sucrose, compressible sugar, confectioners sugar, and the like, and mixtures thereof.

Surfactants may be used to promote wetting of poorly soluble drug as well as promote hydration of alginic acid derivative and include both non-ionic and ionic (cationic, anionic andwitterionic) surfactants suitable for use in pharmaceutical compositions. These include polyethoxylated fatty acids and their derivatives, for example polyethylene glycol 400 distearate, polyethylene glycol-20 dioleate, polyethylene glycol 4-150 mono dilaurate, and polyethylene glycol-20 glyceryl stearate; alcohol-oil transesterification products, for example, polyethylene glycol-6 corn oil; polyglycerized

fatty acids, for example, polyglyceryl-6 pentaoate; propylene glycol fatty acid esters, for example, propylene glycol monocaprylate; mono and diglycerides, for example, glyceryl ricinoleate; sterol and sterol derivatives; sorbitan fatty acid esters and their derivatives, for example polyethylene glycol-20 sorbitan monooleate, and sorbitan monolaurate;

5        polyethylene glycol alkyl ether or phenols, for example polyethylene glycol-20 cetyl ether, polyethylene glycol-10-100 nonyl phenol; sugar esters, for example, sucrose monopalmitate; polyoxyethylene-polyoxypropylene block copolymers known as "poloxamer"; ionic surfactants, for example, sodium caproate, sodium glycocholate, soy lecithin, sodium stearyl fumarate, propylene glycol alginate, octyl sulfosuccinate disodium, and palmitoyl carnitine; and the like; and mixtures thereof.

The pH modifiers are substances which help in maintaining the pH of the local environment surrounding the drug at a value favorable for suitably modifying the solubility behavior of drug and/or gelling behavior of alginic acid derivative. Specific examples of pH modifiers include dibasic sodium phosphate, sodium ascorbate, meglumine, sodium citrate, trimethanolamine, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium oxide, magnesium hydroxide, ammonia, tertiary sodium phosphate, diethanolamine, ethylenediamine, L-lysine and the like, and mixtures thereof

15

20        Specific examples of lubricants/glidants include colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated castor oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, and the like, and mixtures thereof.

25        Specific examples of plasticizers include acetylated triacetin, triethylcitrate, tributylcitrate, glyceroltributylate, monoglyceride, rape oil, olive oil, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethyl phthalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, and the like, and mixtures thereof.

30

Stabilizers include antioxidants, buffers, acids, and the like, and mixtures thereof.

Coloring agents include any FDA approved colors for oral use, and mixtures thereof.

RLL-250WO

PCT/IB03/01771

The term "coating additives" as used herein includes all conventional coating additives used in the art of coating technology and described in the literature. Examples include flux enhancers as well as those described above under pharmaceutically acceptable inert excipients.

5

Flux enhancers are water soluble substances that aid in drawing water from the surrounding media and are thereby helpful in manipulating the semipermeable membrane's permeability. Specific examples include hydroxymethyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, hydroxypropylcellulose, propylene glycol, polyvinylpyrrolidone, and the like, and mixtures thereof.

In one of the embodiments, a monocompartment osmotic controlled drug delivery system is prepared by processes known in the prior art, e.g. by comminuting, mixing, granulation, sizing, filling, molding, spraying, immersing, coating etc. The core is prepared by: (1) blending a poorly soluble drug, at least one alginic acid derivative, optionally an osmotic agent and other pharmaceutically inert excipients; (2) optionally granulating the blend; and (3) compressing the blend/granules into a compact core. The compact core may be enclosed within a semipermeable membrane by applying the composition that forms the semipermeable in the form of a solution/dispersion. The solution or dispersion includes the polymer that forms the semipermeable membrane as well as coating additives. Finally, a passageway may be created through the semipermeable membrane using a suitable technique.

Examples of solvents used for the purpose of granulation or for preparing the solution/dispersion of the coating composition include dichloromethane, isopropyl alcohol, acetone, methanol, ethanol, water, and the like, and mixtures thereof.

Alternatively, additional coating layers may be applied over the cores either below and/or over the semipermeable membrane. The additional layers comprise coating additives and provide smooth surfaces over which the semipermeable membrane may be uniformly applied or identification marks may be printed. In addition, the layer or layers provide an aesthetic appeal.

RLL-250WO

If an immediate action is desired, the monocompartment osmotic controlled delivery system may be coated with an immediate release layer that includes the same drug as in the core, or a different drug over the semipermeable membrane.

5 Further, a combination of more than one drug may also be used in the core and/or in the immediate release layer. For example, if two or more drugs are prescribed to treat a condition and they are suitable for delivery in the monocompartment osmotic controlled delivery system, the drugs may be delivered in the core and/or the core and the immediate release layer.

10

The invention is further illustrated by the following examples, which are provided for illustrative purposes and should not be construed as limiting the scope of the invention.

#### Examples 1a-1c

##### 15 I. Core composition

Ingredient	Weight (mg) per core		
	Example 1a	Example 1b	Example 1c
Glipizide	11.0	11.0	10.0
Sodium alginic acid	-	137.5	100.0
Sorbitol	137.5	-	100.0
Polyvinylpyrrolidone	8.5	8.5	6.3
Magnesium stearate	2.0	2.0	2.2

##### II. Semipermeable membrane composition

Ingredient	% by weight
Cellulose acetate (32% acetyl content)	72.83
Cellulose acetate (39.8% acetyl content)	10.94
Hydroxypropyl methylcellulose	8.11
Polyethylene glycol	8.11

##### Procedure:

20 1. The core ingredients were sieved to the desired size level and the required amounts weighed out.

RLL-250WO

PCT/IB03/01771

2. Glipizide, sodium alginate, sorbitol and polyvinylpyrrolidone were mixed together to form a homogenous blend.
3. The blend of step 2 was granulated using a mixture of isopropyl alcohol and methanol (50:50 v/v).
5. The wet granules were dried in a fluidized bed drier and sized through suitable sieves.
10. The dried granules were lubricated by blending with magnesium stearate and compressed into round concave shaped cores using suitable tooling.
15. Cellulose acetate, hydroxypropyl methylcellulose and polyethylene glycol were dissolved in a mixture of dichloromethane and methanol (80:20 w/w) to prepare a 4% w/w solution.
7. The cores of step 5 were coated with the solution of step 6 in a coating pan until they attained a weight gain of 10% (Example 1a and 1b) or 16% (Example 1c) of core weight.
15. The coated cores were dried in a hot air oven and then an orifice was drilled through the semipermeable membrane using a 1 mm mechanical drill to obtain monocompartment osmotic controlled drug delivery systems.

20. The *in vitro* release of drug (glipizide) from monocompartment osmotic controlled drug delivery systems as per Examples 1a, 1b and 1c was studied in 900 ml phosphate buffer (pH 7.5) using USP II dissolution apparatus, at a paddle speed of 50 rpm. The results of the study are illustrated in Fig-1.

25. Fig-1 demonstrates that both the rate and the amount of drug released for the composition of Example 1a (having no alginic acid derivative) were drastically lower than the rate and amount release for the compositions of Examples 1b and 1c. Hence, alginic acid derivatives play a major role in achieving acceptable release profiles for poorly soluble drugs from monocompartment osmotic controlled drug delivery systems. Further, although the drug release profiles of Example 1b and 1c are very similar, Example 1c (having an osmotic agent) has a lower lag time than Example 1b. Thus, controlling the amount and use of an osmotic agent in combination with an alginic acid derivative is a useful approach in manipulating drug release profiles.

**Examples 2a-2c****I. Core composition**

Ingredient	Weight (mg) per core		
	Example 2a	Example 2b	Example 2c
Glipizide	10.0	10.0	10.0
Sodium alginate	125.0	125.0	125.0
Sorbitol	125.0	62.5	-
Lactose	-	62.5	125.0
Polyvinylpyrrolidone	12.0	12.0	12.0
Magnesium stearate	3.0	3.0	3.0

**II. Semipermeable membrane composition**

Ingredient	% by weight
Cellulose acetate (32% acetyl content)	72.83
Cellulose acetate (39.8% acetyl content)	10.94
Hydroxypropyl methylcellulose	8.11
Polyethylene glycol	8.11

5

**Procedure:**

1. The core ingredients were sieved to the desired size level and the required amounts weighed out.
2. Glipizide, sodium alginate, sorbitol, lactose and polyvinylpyrrolidone were mixed together to form a homogenous blend.
3. The blend of step 2 was granulated using isopropyl alcohol.
4. The wet granules were dried in a fluidized bed drier and sized through suitable sieves.
5. The dried granules were lubricated by blending with magnesium stearate and compressed into round concave shaped cores using suitable tooling.
- 10 6. Cellulose acetate, hydroxypropyl methylcellulose and polyethylene glycol were dissolved in a mixture of dichloromethane and methanol (80:20 w/w) to prepare a 3.5% w/w solution.
7. The cores of step 5 were coated with the solution of step 6 in a coating pan until they attained a weight gain of 17% of core weight.

RLL-250WO

PCT/IB03/01771

8. The coated cores were dried in a hot air oven and then an orifice was drilled through the semipermeable membrane using a 1 mm mechanical drill to obtain monocompartment osmotic controlled drug delivery systems.

5 The *in vitro* release of drug (glipizide) from monocompartment osmotic controlled drug delivery systems as per Examples 2a, 2b, and 2c was studied in 900 ml phosphate buffer (pH 7.5) using USP II dissolution apparatus, at a paddle speed of 50 rpm. The results of the study are illustrated in Fig-2.

10 Fig-2 reveals that though the drug release profiles from Examples 2a, 2b, and 2c are very similar, the lag time for Example 2a (using sorbitol as osmotic agent) is lower than that obtained for Example 2b (using sorbitol and lactose in equal weights as osmotic agents), which is again lower than that obtained for Example 2c (using lactose as osmotic agent). As the solubility of lactose is much less than sorbitol, it can be inferred that with 15 the increase in solubility of osmotic agent, lag time decreases. Hence, delivery systems with the desired lag time may be achieved by proper selection of osmotic agents.

### Example 3

#### I. Core composition

Ingredient	Weight (mg) per core
Glipizide	11.0
Sodium alginate	105.0
Sorbitol	170.0
Colloidal silicon dioxide	2.0
Polyvinylpyrrolidone	15.0
Magnesium stearate	6.0

20

#### II. Precoating composition

Ingredient	% by weight
Hydroxypropyl methylcellulose	80.0
Polyethylene glycol	20.0

RLI-250WO

PCT/IB03/01771

III. Semipermeable membrane

Ingredient	% by weight
Cellulose acetate (32% acetyl content)	72.83
Cellulose acetate (39.8% acetyl content)	10.94
Hydroxypropyl methylcellulose	8.11
Polyethylene glycol	8.11

**Procedure:**

1. The core ingredients were sieved to the desired size level and the required amounts weighed out.
- 5 2. Glipizide, sodium alginate and sorbitol were mixed together to form a homogenous blend.
3. The blend of step 2 was granulated using a solution of polyvinylpyrrolidone in isopropyl alcohol.
- 10 4. The wet granules were dried in a fluidized bed drier and sized through suitable sieves.
5. The dried granules were lubricated by blending with magnesium stearate and compressed into round concave shaped cores using suitable tooling.
- 15 6. Hydroxypropyl methylcellulose and polyethylene glycol were dissolved in a mixture of isopropyl alcohol and dichloromethane (60:40 w/w) to prepare a 5% w/w solution.
7. The cores of step 5 were coated with the solution of step 6 in a coating pan to form a precoated core until they attained a weight gain of 1% of core weight.
8. Cellulose acetate, hydroxypropyl methylcellulose and polyethylene glycol were dissolved in a mixture of dichloromethane and methanol (80:20 w/w) to prepare a 3.5% w/w solution.
- 20 9. The precoated cores of step 7 were coated with the solution of step 8 in a coating pan to prepare five different sets of coated cores having weight gain of 11, 13, 15, 18 and 20% of core weight, respectively.
10. The coated cores of step 10 were dried in a hot air oven and then an orifice was drilled through the semipermeable membrane using a 0.6 mm mechanical drill to obtain monocompartment osmotic controlled drug delivery systems.

RLL-250WO

PCT/IB03/01771

The *in vitro* release of drug (glipizide) from five different sets of monocompartment osmotic controlled drug delivery systems as per composition of Example 3 and with semipermeable membrane thickness equivalent to weight gain of 11, 13, 15, 18 and 20% of core weight respectively, was studied in 900 ml phosphate buffer (pH 7.5) using USP II dissolution apparatus, at a paddle speed of 50 rpm. The results of the study are illustrated in Fig-3.

The drug release profiles in Fig-3 clearly indicate a decrease in drug release rate with an increase in the semipermeable membrane thickness equivalent to above 18% weight gain of core weight. Hence, controlling the thickness of the semipermeable membrane can be used to manipulate the drug release profiles.

#### Example 4a-4d

##### I. Core composition

Ingredient	Weight (mg) per core			
	Example No.			
	4a	4b	4c	4d
Doxazosin mesylate	10.7	10.7	10.7	10.7
Sodium alginate	135.0	100.0	100.0	137.3
Sorbitol	135.0	170.0	170.0	134.7
Colloidal silicon dioxide	2.0	2.0	2.0	2.6
Polyvinylpyrrolidone	14.3	14.3	14.3	15.3
Magnesium oxide	-	30.0	-	-
Meglumine	-	-	30.0	-
Poloxamer	-	-	-	10.0
Magnesium stearate	3.0	3.0	3.0	4.6

15

RLL-250WO

PCT/IB03/01771

II. Semipermeable membrane composition

Ingredient	% by weight	
	Example 4a-4c	Example 4d
Cellulose acetate (39.8% acetyl content)	77.0	83.9
Hydroxypropyl methylcellulose	-	8.0
Polyethylene glycol 4000	11.5	8.0
Polyethylene glycol 400	11.5	-

**Procedure:**

5        1. The core ingredients were sieved to the desired size level and the required amounts weighed out.

2. Doxazosin mesylate, sodium alginate, sorbitol, polyvinylpyrrolidone, colloidal silicon dioxide, magnesium oxide (Example 4b), meglumine (Example 4c) and poloxamer (Example 4d) were mixed together to form homogenous blends.

10      3. The blends of step 2 were lubricated by blending with magnesium stearate and compressed into round concave shaped cores using suitable tooling.

4. Cellulose acetate and polyethylene glycol were dissolved in a mixture of acetone and water (90:10 w/w) to prepare a 4% w/w solution (Example 4a-4c), whereas for Example 4d cellulose acetate, polyethylene glycol and hydroxypropyl methylcellulose were dissolved in a mixture of dichloromethane and methanol (80:20 w/w) to prepare a 3.5% w/w solution.

15      5. The cores of step 5 were coated with the corresponding coating solutions of step 6 in a coating pan until they attained a weight gain of 11% (Example 4a) or 12% (Example 4b, 4c and 4d) of core weight.

20      6. The coated cores were dried in a hot air oven and then an orifice was drilled through the semipermeable membrane using a 0.6 mm mechanical drill to obtain monocompartment osmotic controlled drug delivery systems.

The *in vitro* release of drug (doxazosin mesylate) from monocompartment osmotic controlled drug delivery systems as per Examples 4a-4d was studied in 900 ml phosphate

buffer (pH 6.8) with 0.5% sodium lauryl sulphate using USP II dissolution apparatus, at a paddle speed of 50 rpm. The results of the study are illustrated in Fig-4.

### Example 5

#### 5 I. Core composition

Ingredient	Weight (mg) per core
Cilostazol	200.0
Sodium alginate	80.0
Sorbitol	52.0
Lactose	50.0
Polyvinylpyrrolidone	15.0
Sodium lauryl sulphate	20.0
Magnesium stearate	3.0

#### II. Semipermeable membrane

Ingredient	% by weight
Cellulose acetate (39.8% acetyl content)	74.07
Polyethylene glycol 4000	14.82
Polyethylene glycol 400	11.11

#### Procedure:

- 10 1. The core ingredients were sieved to the desired size level and the required amounts weighed out.
2. Cilostazol, sodium alginate, sorbitol, lactose, sodium lauryl sulphate and polyvinylpyrrolidone were mixed together to form a homogenous blend.
3. The blend of step 2 was granulated using isopropyl alcohol.
- 15 4. The wet granules of step 3 were dried and sieved through suitable sieves.
5. The dried granules were lubricated by blending with magnesium stearate and compressed into round concave shaped cores using suitable tooling.
6. Cellulose acetate and polyethylene glycol were dissolved in a mixture of acetone and water (90:10 w/w) to prepare a 4% w/w solution.
- 20 7. The cores of step 5 were coated with the solution of step 6 in a coating pan to prepare two different sets of coated cores having weight gains of 7.6% and 10.8% of core weight, respectively.

RLL-250WO

PCT/IB03/01771

8. The coated cores of step 7 were dried in a hot air oven and then an orifice was drilled through the semipermeable membrane using a 0.6 mm mechanical drill to obtain monocompartment osmotic controlled drug delivery systems.

5        The *in vitro* release of drug (Cilostazol) from the two different sets of monocompartment osmotic controlled drug delivery systems as per the compositions of Example 5 and with semipermeable membrane thickness equivalent to weight gains of 7.6% and 10.8% of core weight, respectively, was studied in 900 ml phosphate buffer (pH 6.8) with 0.25% sodium lauryl sulphate using USP II dissolution apparatus, at a paddle speed of 50 rpm. The results of the study are illustrated in Fig-5.

10      While several particular forms of the invention have been illustrated and described, it will be apparent that various modifications and combinations of the invention detailed in the text and claims can be made without departing from the spirit and scope of the invention. For example, each monocompartment osmotic controlled delivery system can include approximately 2.5 mg, 5 mg, or 10 mg of glipizide. Moreover, it is contemplated that any single feature or any combination of optional features of the inventive variations described herein may be specifically excluded from the claimed invention and be so described as a negative invention. Accordingly, it is not intended that the invention be limited, except as by the appended claims.

22

06/05 '03 MAR 23:15 [N° TX/RX 6266]

RII-250WO

PCT/IB03/01771

**WE CLAIM:**

1        1. A monocompartment osmotic controlled drug delivery system comprising a  
2 poorly soluble drug and at least one alginic acid derivative.

1        2. The monocompartment osmotic controlled drug delivery system of claim 1,  
2 further comprising a core, a semipermeable membrane enclosing at least a part of the core,  
3 and at least one passageway in the semipermeable membrane configured to deliver the  
4 contents of the core into the surrounding media, wherein the core comprises the poorly  
5 soluble drug, the at least one alginic acid derivative, and at least one pharmaceutically  
6 acceptable inert excipient.

1        3. The monocompartment osmotic controlled drug delivery system of claim 2,  
2 wherein the core further comprises an osmotic agent.

1        4. The monocompartment osmotic controlled drug delivery system of claim 2,  
2 wherein the core comprises one or more additional layers below and/or above the  
3 semipermeable membrane.

1        5. The monocompartment osmotic controlled drug delivery system of claim 4,  
2 wherein the one or more additional layers comprise an immediate release layer of drug,  
3 wherein the drug comprises the same or different drug as in the core.

1        6. The monocompartment osmotic controlled drug delivery system of claim 2,  
2 wherein the core comprises a compact composition having a shape.

1        7. The monocompartment osmotic controlled drug delivery system of claim 1,  
2 wherein the drug comprises a single drug or a combination of drugs.

1        8. The monocompartment osmotic controlled drug delivery system of claim 2,  
2 wherein the poorly soluble drug comprises one or more of an antidiabetic, antineoplastic  
3 agent, antihypertensive, psychopharmacological agent, cardiovascular agent, platelet  
4 aggregation inhibitor, analgesic, antimicrobial, diuretic, or spasmolytic.

1        9. The monocompartment osmotic controlled drug delivery system of claim 8,  
2 wherein the poorly soluble drug comprises one or more of glipizide, doxazosin, verapamil,

RLL-250WO

3 prazosin, isradipine, cilostazol, nifedipine, nisoldipine, bendroflumethazide,  
4 chlorpropamide, hydrocortisone, ibuprofen, and diclofenac.

1 10. The monocompartment osmotic controlled drug delivery system of claim 9,  
2 wherein the poorly soluble drug comprises glipizide.

1 11. The monocompartment osmotic controlled drug delivery system of claim 9,  
2 wherein the poorly soluble drug comprises doxazosin.

1 12. The monocompartment osmotic controlled drug delivery system of claim 9,  
2 wherein the poorly soluble drug comprises cilostazol.

1 13. The monocompartment osmotic controlled drug delivery system of claim 1,  
2 wherein the alginic acid derivative comprises one or more of alginic acid and its  
3 pharmaceutically acceptable salts, pharmaceutically acceptable esters, or other  
4 pharmaceutically acceptable derivatives..

1 14. The monocompartment osmotic controlled drug delivery system of claim  
2 13, wherein the alginic acid salt comprises one or more salts of alginic acid with sodium,  
3 potassium, magnesium, calcium or ammonia.

1 15. The monocompartment osmotic controlled drug delivery system of claim  
2 14, wherein the salt of alginic acid comprises sodium alginate.

1 16. The monocompartment osmotic controlled drug delivery system of claim  
2 13, wherein the alginic acid ester comprises propylene glycol alginate.

1 17. The monocompartment osmotic controlled drug delivery system of claim 2,  
2 wherein the pharmaceutically acceptable inert excipient comprises one or more of binders,  
3 diluents, surfactants, pH modifiers, lubricants/glidants, stabilizers, plasticizers, and  
4 coloring agents.

1 18. The monocompartment osmotic controlled drug delivery system of claim 2,  
2 wherein the semipermeable membrane comprises one or more of semipermeable  
3 membrane-forming polymers and one or more coating additives.

1 19. The monocompartment osmotic controlled drug delivery system of claim  
2 18, wherein the semipermeable membrane-forming polymer comprises one or more of

3 cellulose derivatives, cellulose acetate, cellulose triacetate, agar acetate, amylose acetate,  
4 cellulose acetate ethyl carbamate, cellulose acetate phthalate, cellulose acetate methyl  
5 carbamate, cellulose acetate succinate, cellulose acetate dimethylaminoacetate, cellulose  
6 acetate ethyl carbonate, cellulose acetate chloroacetate, cellulose acetate ethyl oxalate,  
7 cellulose acetate methyl sulphonate, cellulose acetate butyl sulphonate, cellulose acetate  
8 propionate, cellulose acetate diethylamino-acetate, cellulose acetate octate, cellulose  
9 acetate laurate, cellulose acetate p-toluenesulphonate, cellulose acetate butyrate, polymeric  
10 epoxides, copolymers of alkylene oxides and alkyl glycidyl ethers, polyglycols, polylactic  
11 acid derivatives, and copolymers of acrylic acid ethyl ester and methacrylic acid methyl  
12 ester.

1        20. The monocompartment osmotic controlled drug delivery system of claim  
2 19, wherein the cellulose derivative comprises cellulose acetate.

1        21. The monocompartment osmotic controlled drug delivery system of claim  
2 20, wherein the semipermeable membrane-forming polymer comprises a combination of  
3 cellulose acetates having different degrees of acetylation.

1        22. The monocompartment osmotic controlled drug delivery system of claim  
2 18, wherein the coating additives comprises one or more of flux enhancers and  
3 pharmaceutically acceptable inert excipients.

1        23. The monocompartment osmotic controlled drug delivery system of claim  
2 22, wherein the flux enhancer comprises one or more of hydroxymethyl cellulose,  
3 hydroxypropyl methylcellulose, polyethylene glycol, hydroxypropylcellulose, propylene  
4 glycol, and polyvinylpyrrolidone.

1        24. The monocompartment osmotic controlled drug delivery system of claim  
2 23, wherein the flux enhancer comprises hydroxypropyl methylcellulose.

1        25. The monocompartment osmotic controlled drug delivery system of claim  
2 23, wherein the flux enhancer comprises polyethylene glycol.

1        26. The monocompartment osmotic controlled drug delivery system of claim 3,  
2 wherein the osmotic agent comprises one or more of water soluble salts of inorganic acids,

RLL-250WO

3 water soluble salts of organic acids, non ionic organic compounds having high water  
4 solubility, water-soluble amino acids, urea, and urea derivatives.

1 27. The monocompartment osmotic controlled drug delivery system of claim  
2 26, wherein the one or more water soluble salts of inorganic acids comprises magnesium  
3 chloride, magnesium sulfate, lithium chloride, sodium chloride, potassium chloride,  
4 lithium hydrogen phosphate, sodium hydrogen phosphate, potassium hydrogen phosphate,  
5 lithium dihydrogen phosphate, sodium dihydrogen phosphate, and potassium dihydrogen  
6 phosphate.

1 28. The monocompartment osmotic controlled drug delivery system of claim  
2 26, wherein the water soluble salts of organic acids comprise one or more of sodium  
3 acetate, potassium acetate, magnesium succinate, sodium benzoate, sodium citrate, and  
4 sodium ascorbate.

1 29. The monocompartment osmotic controlled drug delivery system of claim  
2 26, wherein the non ionic organic compounds having high water solubility comprise one  
3 or more carbohydrate, wherein carbohydrate comprises one or more of mannitol, sorbitol,  
4 arabinose, ribose, xylose, glucose, fructose, mannose, galactose, sucrose, maltose, lactose,  
5 and raffinose.

1 30. The monocompartment osmotic controlled drug delivery system of claim  
2 26, wherein the water-soluble amino acids comprises one or more of glycine, leucine,  
3 alanine, and methionine.

1 31. The monocompartment osmotic controlled drug delivery system of claim  
2 26, wherein the osmotic agent comprises sorbitol.

1 32. The monocompartment osmotic controlled drug delivery system of claim  
2 26, wherein the osmotic agent comprises lactose.

1 33. The monocompartment osmotic controlled drug delivery system of claim  
2 10, wherein the poorly soluble drug comprises glipizide present at approximately 2.5 mg.

1 34. The monocompartment osmotic controlled drug delivery system of claim  
2 10, wherein the poorly soluble drug comprises glipizide present at approximately 5 mg.

RLL-250WO

1        35. The monocompartment osmotic controlled drug delivery system of claim  
2 10, wherein the poorly soluble comprise glipizide present at approximately 10 mg.

1        36. A process for the preparation of a monocompartment osmotic controlled  
2 drug delivery device, comprising the steps of:  
3        blending a poorly soluble drug, at least one alginic acid derivative, and at least one  
4 pharmaceutically acceptable inert excipient; and  
5        compressing the blend into a compact core;  
6        enclosing the core with a solution/dispersion of an enclosing composition  
7 comprising one or more semipermeable membrane-forming polymers and other coating  
8 additives; and  
9        forming at least one passageway in the semipermeable membrane.

1        37. The process of claim 36, further comprising granulating the blend with a  
2 binder before compressing the blend into a compact core.

1        38. The process of claim 36, further comprising blending at least one alginic  
2 acid derivative with the blend.

1        39. The process of claim 36, wherein the solution/dispersion of the enclosing  
2 composition is made in a solvent comprising one or more of dichloromethane, isopropyl  
3 alcohol, acetone, methanol, ethanol, and water.


1        40. The process of claim 37, wherein the granulation is made in a solvent  
2 comprising one or more of dichloromethane, isopropyl alcohol, acetone, methanol,  
3 ethanol, and water.

1        41. A method of achieving controlled delivery of a poorly soluble drug over a  
2 period of at least 4 hours, the method comprising providing a monocompartment osmotic  
3 controlled drug delivery system comprising a poorly soluble drug and at least one alginic  
4 acid derivative.


Abstract of the Invention

The present invention relates to a monocompartment osmotic controlled drug delivery system comprising a poorly soluble drug and at least one alginic acid derivative.


Y5




2/5




315



5/4



5/5



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**